Percutaneous left atrial appendage occlusion: A South African experience

BACKGROUND: Atrial fibrillation (AF) is associated with all-cause mortality, heart failure and non-fatal stroke, and thromboprophylaxis is traditionally provided with oral anticoagulants (OACs). Percutaneous left atrial appendage occlusion (LAAO) with a dedicated device is an alternative approach to thromboprophylaxis in patients with AF who are: (i) intolerant to OACs (e.g. life-threatening haemorrhage); (ii) non-adherent to OACs; or (iii) at a high bleeding risk with OACs. Non-inferiority of LAAO compared with OACs was demonstrated in e.g. the WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation (PROTECT AF) trial. Only very limited data are available on percutaneous LAAO in South Africa (SA), and no local outcome data have been reportedOBJECTIVES: To compare the safety and efficacy outcomes of an SA percutaneous LAAO programme with larger international seriesMETHODS: All patients undergoing percutaneous LAAO from 2013 to 2020 at a single centre (SAEndovascular, Kuils River Netcare Hospital, SA) were included from an ongoing registry. Survival analysis was performed with the Kaplan-Meier methodRESULTS: Of 101 LAAO recipients (mean (standard deviation) age 77 (10) years, 64% male) analysed, 90 (90%) had permanent AF, 1 (1%) persistent AF and 9 (9%) paroxysmal AF. The most common indication for LAAO was previous severe bleeding (n=23; 23%). The mean device size was 23 (3) mm and the procedural success rate was 98%. After a median (interquartile range) follow-up of 21 (5 - 41) months, 6 patients (6%) experienced stroke or all-cause mortality. Four patients (4%) had a life-threatening procedural complication (tamponade n=2 (2%) and device embolisation n=2 (2%)). These outcomes are comparable to large international series, e.g. PROTECT AFCONCLUSIONS: The safety and efficacy outcomes of an SA percutaneous LAAO programme were comparable to large international series. A successful percutaneous LAAO programme is feasible in a southern African context

Saved in:
Bibliographic Details
Main Authors: Dippenaar,A P, Saaiman,J A, Brink,P A, Heradien,M J, van der Bijl,P
Format: Digital revista
Language:English
Published: South African Medical Association 2022
Online Access:http://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S0256-95742022000400007
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0256-95742022000400007
record_format ojs
spelling oai:scielo:S0256-957420220004000072022-05-18Percutaneous left atrial appendage occlusion: A South African experienceDippenaar,A PSaaiman,J ABrink,P AHeradien,M Jvan der Bijl,PBACKGROUND: Atrial fibrillation (AF) is associated with all-cause mortality, heart failure and non-fatal stroke, and thromboprophylaxis is traditionally provided with oral anticoagulants (OACs). Percutaneous left atrial appendage occlusion (LAAO) with a dedicated device is an alternative approach to thromboprophylaxis in patients with AF who are: (i) intolerant to OACs (e.g. life-threatening haemorrhage); (ii) non-adherent to OACs; or (iii) at a high bleeding risk with OACs. Non-inferiority of LAAO compared with OACs was demonstrated in e.g. the WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation (PROTECT AF) trial. Only very limited data are available on percutaneous LAAO in South Africa (SA), and no local outcome data have been reportedOBJECTIVES: To compare the safety and efficacy outcomes of an SA percutaneous LAAO programme with larger international seriesMETHODS: All patients undergoing percutaneous LAAO from 2013 to 2020 at a single centre (SAEndovascular, Kuils River Netcare Hospital, SA) were included from an ongoing registry. Survival analysis was performed with the Kaplan-Meier methodRESULTS: Of 101 LAAO recipients (mean (standard deviation) age 77 (10) years, 64% male) analysed, 90 (90%) had permanent AF, 1 (1%) persistent AF and 9 (9%) paroxysmal AF. The most common indication for LAAO was previous severe bleeding (n=23; 23%). The mean device size was 23 (3) mm and the procedural success rate was 98%. After a median (interquartile range) follow-up of 21 (5 - 41) months, 6 patients (6%) experienced stroke or all-cause mortality. Four patients (4%) had a life-threatening procedural complication (tamponade n=2 (2%) and device embolisation n=2 (2%)). These outcomes are comparable to large international series, e.g. PROTECT AFCONCLUSIONS: The safety and efficacy outcomes of an SA percutaneous LAAO programme were comparable to large international series. A successful percutaneous LAAO programme is feasible in a southern African contextSouth African Medical AssociationSAMJ: South African Medical Journal v.112 n.4 20222022-04-01journal articletext/htmlhttp://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S0256-95742022000400007en
institution SCIELO
collection OJS
country Sudáfrica
countrycode ZA
component Revista
access En linea
databasecode rev-scielo-za
tag revista
region África del Sur
libraryname SciELO
language English
format Digital
author Dippenaar,A P
Saaiman,J A
Brink,P A
Heradien,M J
van der Bijl,P
spellingShingle Dippenaar,A P
Saaiman,J A
Brink,P A
Heradien,M J
van der Bijl,P
Percutaneous left atrial appendage occlusion: A South African experience
author_facet Dippenaar,A P
Saaiman,J A
Brink,P A
Heradien,M J
van der Bijl,P
author_sort Dippenaar,A P
title Percutaneous left atrial appendage occlusion: A South African experience
title_short Percutaneous left atrial appendage occlusion: A South African experience
title_full Percutaneous left atrial appendage occlusion: A South African experience
title_fullStr Percutaneous left atrial appendage occlusion: A South African experience
title_full_unstemmed Percutaneous left atrial appendage occlusion: A South African experience
title_sort percutaneous left atrial appendage occlusion: a south african experience
description BACKGROUND: Atrial fibrillation (AF) is associated with all-cause mortality, heart failure and non-fatal stroke, and thromboprophylaxis is traditionally provided with oral anticoagulants (OACs). Percutaneous left atrial appendage occlusion (LAAO) with a dedicated device is an alternative approach to thromboprophylaxis in patients with AF who are: (i) intolerant to OACs (e.g. life-threatening haemorrhage); (ii) non-adherent to OACs; or (iii) at a high bleeding risk with OACs. Non-inferiority of LAAO compared with OACs was demonstrated in e.g. the WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation (PROTECT AF) trial. Only very limited data are available on percutaneous LAAO in South Africa (SA), and no local outcome data have been reportedOBJECTIVES: To compare the safety and efficacy outcomes of an SA percutaneous LAAO programme with larger international seriesMETHODS: All patients undergoing percutaneous LAAO from 2013 to 2020 at a single centre (SAEndovascular, Kuils River Netcare Hospital, SA) were included from an ongoing registry. Survival analysis was performed with the Kaplan-Meier methodRESULTS: Of 101 LAAO recipients (mean (standard deviation) age 77 (10) years, 64% male) analysed, 90 (90%) had permanent AF, 1 (1%) persistent AF and 9 (9%) paroxysmal AF. The most common indication for LAAO was previous severe bleeding (n=23; 23%). The mean device size was 23 (3) mm and the procedural success rate was 98%. After a median (interquartile range) follow-up of 21 (5 - 41) months, 6 patients (6%) experienced stroke or all-cause mortality. Four patients (4%) had a life-threatening procedural complication (tamponade n=2 (2%) and device embolisation n=2 (2%)). These outcomes are comparable to large international series, e.g. PROTECT AFCONCLUSIONS: The safety and efficacy outcomes of an SA percutaneous LAAO programme were comparable to large international series. A successful percutaneous LAAO programme is feasible in a southern African context
publisher South African Medical Association
publishDate 2022
url http://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S0256-95742022000400007
work_keys_str_mv AT dippenaarap percutaneousleftatrialappendageocclusionasouthafricanexperience
AT saaimanja percutaneousleftatrialappendageocclusionasouthafricanexperience
AT brinkpa percutaneousleftatrialappendageocclusionasouthafricanexperience
AT heradienmj percutaneousleftatrialappendageocclusionasouthafricanexperience
AT vanderbijlp percutaneousleftatrialappendageocclusionasouthafricanexperience
_version_ 1756006002879102976